Galectin 3 and Galectin 3 Binding Protein Improve the Risk Stratification after Myocardial Infarction
暂无分享,去创建一个
G. Biolo | G. Barbati | G. Sinagra | T. Not | N. Fiotti | A. Beltrami | A. Aleksova | E. Stenner | A. Paldino | F. Ziberna | G. Gagno | L. Padoan | Alessandro Beleù | C. Hiche | Alessandro Beleù
[1] G. Hindricks,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.
[2] Yuqi Cui,et al. Elevated plasma levels of Mac-2 binding protein predict poor cardiovascular outcomes in patients with acute coronary syndrome , 2017, Coronary artery disease.
[3] M. Enriquez-Sarano,et al. Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective. , 2017, The American journal of medicine.
[4] V. Bazan,et al. Galectin-3 in acute coronary syndrome. , 2017, Clinical biochemistry.
[5] P. Libby,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.
[6] C. Gleissner,et al. Galectin-3 binding protein, coronary artery disease and cardiovascular mortality: Insights from the LURIC study. , 2017, Atherosclerosis.
[7] G. Can,et al. Long-term prognostic significance of pentraxin-3 in patients with acute myocardial infarction: 5-year prospective cohort study , 2016, Anatolian journal of cardiology.
[8] N. Ohte,et al. Serum levels of Mac-2 binding protein increase with cardiovascular risk and reflect silent atherosclerosis. , 2016, Atherosclerosis.
[9] R. De Maria,et al. Galectin-3 predicts left ventricular remodelling after anterior-wall myocardial infarction treated by primary percutaneous coronary intervention , 2016, Heart.
[10] M. Sabatine,et al. Multimarker Risk Stratification in Patients With Acute Myocardial Infarction , 2016, Journal of the American Heart Association.
[11] L. Tavazzi,et al. Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HF. , 2016, Clinical chemistry.
[12] D. Streiner,et al. Biomarkers of Host Response Predict Primary End-Point Radiological Pneumonia in Tanzanian Children with Clinical Pneumonia: A Prospective Cohort Study , 2015, PloS one.
[13] S. Al-Salam,et al. Galectin-3 is expressed in the myocardium very early post-myocardial infarction. , 2015, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[14] J. Spertus,et al. Risk Factors for Rehospitalization for Acute Coronary Syndromes and Unplanned Revascularization Following Acute Myocardial Infarction , 2015, Journal of the American Heart Association.
[15] E. Malchiodi,et al. Galectin-3 is essential for early wound healing and ventricular remodeling after myocardial infarction in mice. , 2014, International journal of cardiology.
[16] M. Schocke,et al. Galectin-3: relation to infarct scar and left ventricular function after myocardial infarction. , 2013, International journal of cardiology.
[17] Erling Falk,et al. Update on acute coronary syndromes: the pathologists' view. , 2013, European heart journal.
[18] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.
[19] C. Heeschen,et al. Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome , 2010, Heart.
[20] Sonia S. Anand,et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. , 2008, European heart journal.
[21] E. Lee,et al. Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity. , 2007, Clinical and experimental rheumatology.
[22] K. Eagle,et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) , 2006, BMJ : British Medical Journal.
[23] Mirna Flögel,et al. Galectin-3: an open-ended story. , 2006, Biochimica et biophysica acta.
[24] S. Yusuf,et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.
[25] S. Lemon,et al. Classification and regression tree analysis in public health: Methodological review and comparison with logistic regression , 2003, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.
[26] S. de Servi,et al. Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study. , 2003, European heart journal.
[27] Nader Rifai,et al. Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.
[28] A. Siegbahn,et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.
[29] P. Ridker,et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.
[30] A. Folsom,et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. , 1998, The New England journal of medicine.
[31] M. Pfeffer,et al. Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.
[32] Coronavirus Will Be in the Top 10 Causes of Death , 2020 .
[33] J. Mehilli,et al. [2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)]. , 2016, Giornale italiano di cardiologia.
[34] D. Pascual-Figal,et al. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. , 2015, JACC. Heart failure.
[35] Cheuk-Kwan Sun,et al. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. , 2012, Journal of atherosclerosis and thrombosis.
[36] Maarten L. Simoons,et al. The third universal definition of myocardial infarction , 2013 .
[37] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .